Serodiagnostic markers for the prediction of the outcome of intensive phase tuberculosis therapy

Tuberculosis

Volumn 93, Issue 2, 2013, Pages 239-245

  Baumann, Ralf ^a,b,c,e   Kaempfer, Susanne ^b   Chegou, Novel N ^a   Nene, Nonhlanhla F ^a   Veenstra, Hanne ^a   Spallek, Ralf ^b   Bolliger, Chris T ^c   Lukey, Pauline T ^d   Van Helden, Paul D ^a   Singh, Mahavir ^b   Walzl, Gerhard ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b LIONEX DIAGNOSTICS AND THERAPEUTICS GMBH   (Germany)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

^d GLAXOSMITHKLINE   (United Kingdom)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Relapse; Serodiagnosis; Sputum culture conversion; Treatment failure; Tuberculosis

Indexed keywords

ABC TRANSPORTER; ALANINE DEHYDROGENASE; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; IMMUNOGLOBULIN G; PSTS3 PROTEIN; TPX PROTEIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC THERAPY; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; FEMALE; HUMAN; INTENSIVE CARE; LUNG TUBERCULOSIS; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SPUTUM; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84875128404     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2012.09.003     Document Type: Article

References (52)

1. Treatment of tuberculosis MMWR Recomm Rep 52 RR-11 2003 1 77
2. R.M. Jasmer, C.B. Seaman, L.C. Gonzalez, L.M. Kawamura, D.H. Osmond, and C.L. Daley Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy Am J Respir Crit Care Med 170 5 2004 561 566
3. J.A.C. Luna Tuberculosis guide for specialist physicians 2004 International Union Against Tuberculosis and Lung Disease Paris
4. Z. Temesgen, L.M. Baddour, and J.M. Steckelberg Mayo clinic infectious diseases board review 2012 Mayo Clinic Scientific Press; Oxford University Press [Rochester, Minn.], New York
5. D.A. Enarson Management of tuberculosis: a guide for low income countries 5th ed. 2000 Paris
6. R.S. Wallis, S. Patil, S.H. Cheon, K. Edmonds, M. Phillips, M.D. Perkins, M. Joloba, A. Namale, J.L. Johnson, L. Teixeira, R. Dietze, S. Siddiqi, R.D. Mugerwa, K. Eisenach, and J.J. Ellner Drug tolerance in Mycobacterium tuberculosis Antimicrob Agents Chemother 43 11 1999 2600 2606
7. F. March, X. Garriga, P. Rodríguez, C. Moreno, M. Garrigó, P. Coll, and G. Prats Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis Clin Infect Dis 25 5 1997 1044 1047
8. R.B. Deoskar, B. Sengupta, K.E. Rajan, S. Barthwa, J. Falleiro, and S.K. Sharma Study of drug resistant pulmonary tuberculosis MJAFI 61 2005 245 248
9. D. Benator, M. Bhattacharya, L. Bozeman, W. Burman, A. Cantazaro, R. Chaisson, F. Gordin, C.R. Horsburgh, J. Horton, A. Khan, C. Lahart, B. Metchock, C. Pachucki, L. Stanton, A. Vernon, M.E. Villarino, Y.C. Wang, M. Weiner, and S. Weis Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial Lancet 360 9332 2002 528 534
10. D.A. Mitchison Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months Am Rev Respir Dis 147 4 1993 1062 1063
11. V.R. Aber, and A.J. Nunn Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy Bull Int Union Tuberc 53 4 1978 276 280
12. M. Zierski, E. Bek, M.W. Long, and D.E. Snider Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment Am Rev Respir Dis 122 6 1980 879 889
13. C. Sánchez-Rodríguez, C. Estrada-Chávez, J. García-Vigil, F. Laredo-Sánchez, J. Halabe-Cherem, A. Pereira-Suárez, and R. Mancilla An IgG antibody response to the antigen 85 complex is associated with good outcome in Mexican Totonaca Indians with pulmonary tuberculosis Int J Tuberc Lung Dis 6 8 2002 706 712
14. A. Azzurri, G.V. Kanaujia, O.Y. Sow, B. Bah, A. Diallo, G. Del Prete, and M.L. Gennaro Serological markers of pulmonary tuberculosis and of response to anti-tuberculosis treatment in a patient population in Guinea Int J Immunopathol Pharmacol 19 1 2006 199 208
15. S. den Boon, S.W. van Lill, M.W. Borgdorff, D.A. Enarson, S. Verver, E.D. Bateman, E. Irusen, C.J. Lombard, N.W. White, C. de Villiers, and N. Beyers High prevalence of tuberculosis in previously treated patients, Cape Town, South Africa Emerging Infect Dis 13 8 2007 1189 1194
16. T. Roberts, N. Beyers, A. Aguirre, and G. Walzl Immunosuppression during active tuberculosis is characterized by decreased interferon-gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor-beta and interleukin-4 mRNA levels J Infect Dis 195 6 2007 870 878
17. H. Veenstra, R. Baumann, N.M. Carroll, P.T. Lukey, M. Kidd, N. Beyers, C.T. Bolliger, P.D. van Helden, and G. Walzl Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders Clin Exp Immunol 145 2 2006 252 260
18. H. Veenstra, R. Baumann, P.T. Lukey, N. Beyers, P.D. van Helden, and G. Walzl High levels of intracellular IL-4 are expressed in circulating apoptotic T cells in patients with tuberculosis and in community controls Tuberculosis (Edinb) 88 1 2008 21 30
19. J.F. Djoba Siawaya, N.B. Bapela, K. Ronacher, H. Veenstra, M. Kidd, R. Gie, N. Beyers, P. van Helden, and G. Walzl Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response J Infect 56 5 2008 340 347
20. A.M. Mandalakas, A.C. Hesseling, N.N. Chegou, H.L. Kirchner, X. Zhu, B.J. Marais, G.F. Black, N. Beyers, and G. Walzl High level of discordant IGRA results in HIV-infected adults and children Int J Tuberc Lung Dis 12 4 2008 417 423
21. B. Hutter, and M. Singh Host vector system for high-level expression and purification of recombinant, enzymatically active alanine dehydrogenase of Mycobacterium tuberculosis Gene 212 1 1998 21 29
22. B. Hutter, and M. Singh Properties of the 40 kDa antigen of Mycobacterium tuberculosis, a functional L-alanine dehydrogenase Biochem J 343 Pt 3 1999 669 672
23. Y. Benjamini, and Y. Hochberg Controlling the false discovery rate: a practical and powerful approach to multiple testing J Royal Stat Soc B 57 1995 289 300
24. T.J. Hastie, R.J. Tibshirani, and J. Friedman The elements of statistical learning: data mining, inference, and prediction 10th ed. 2008 Springer New York, NY
25. J.F. Djoba Siawaya, N. Beyers, P. van Helden, and G. Walzl Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis Clin Exp Immunol 156 1 2009 69 77
26. J.F. Djoba Siawaya, N.B. Bapela, K. Ronacher, N. Beyers, P. van Helden, and G. Walzl Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment Clin Vaccine Immunol 15 8 2008 1165 1170
27. L.E. Desjardin, M.D. Perkins, K. Wolski, S. Haun, L. Teixeira, Y. Chen, J.L. Johnson, J.J. Ellner, R. Dietze, J. Bates, M.D. Cave, and K.D. Eisenach Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy Am J Respir Crit Care Med 160 1 1999 203 210
28. T.J. Hellyer, L.E. Desjardin, L. Teixeira, M.D. Perkins, M.D. Cave, and K.D. Eisenach Detection of viable Mycobacterium tuberculosis by reverse transcriptase-strand displacement amplification of mRNA J Clin Microbiol 37 3 1999 518 523
29. R.S. Wallis, M.D. Perkins, M. Phillips, M. Joloba, A. Namale, J.L. Johnson, C.C. Whalen, L. Teixeira, B. Demchuk, R. Dietze, R.D. Mugerwa, K. Eisenach, and J.J. Ellner Predicting the outcome of therapy for pulmonary tuberculosis Am J Respir Crit Care Med 161 4 Pt 1 2000 1076 1080
30. G. Walzl, K. Ronacher, J.F. Djoba Siawaya, and H.M. Dockrell Biomarkers for TB treatment response: challenges and future strategies J Infect 57 2 2008 103 109
31. M. Henao-Tamayo, S.M. Irwin, S. Shang, D. Ordway, and I.M. Orme T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis Tuberculosis (Edinb) 91 4 2011 308 313
32. V.H. Sai Priya, B. Anuradha, S. Latha Gaddam, S.E. Hasnain, K.J.R. Murthy, and V.L. Valluri In vitro levels of interleukin 10 (IL-10) and IL-12 in response to a recombinant 32-kilodalton antigen of Mycobacterium bovis BCG after treatment for tuberculosis Clin Vaccine Immunol 16 1 2009 111 115
33. Y. Chen, H. Chang, C. Chen, S. Liu, C. Chin, C. Wu, T. Chao, C. Lie, C. Wang, and M. Lin Blood absolute T cell counts may predict 2-month treatment response in patients with pulmonary tuberculosis Dis Markers 28 6 2010 343 352
34. R.S. Wallis, M. Pai, D. Menzies, T.M. Doherty, G. Walzl, M.D. Perkins, and A. Zumla Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice Lancet 375 9729 2010 1920 1937
35. C. Lienhardt, J. Rowley, and K. Manneh Directly observed treatment for tuberculosis Lancet 353 9147 1999 145 146 author reply 147-8
36. A.C. Hesseling, G. Walzl, D.A. Enarson, N.M. Carroll, K. Duncan, P.T. Lukey, C. Lombard, P.R. Donald, K.A. Lawrence, R.P. Gie, P.D. van Helden, and N. Beyers Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients Int J Tuberc Lung Dis 14 5 2010 560 570
37. M.S. Imaz, and E. Zerbini Antibody response to culture filtrate antigens of Mycobacterium tuberculosis during and after treatment of tuberculosis patients Int J Tuberc Lung Dis 4 6 2000 562 569
38. A. Demissie, M. Abebe, A. Aseffa, G. Rook, H. Fletcher, A. Zumla, K. Weldingh, I. Brock, P. Andersen, and T.M. Doherty Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2 J Immunol 172 11 2004 6938 6943
39. I. Rosenkrands, A. King, K. Weldingh, M. Moniatte, E. Moertz, and P. Andersen Towards the proteome of Mycobacterium tuberculosis Electrophoresis 21 17 2000 3740 3756
40. I. Rosenkrands, K. Weldingh, S. Jacobsen, C.V. Hansen, W. Florio, I. Gianetri, and P. Andersen Mapping and identification of Mycobacterium tuberculosis proteins by two-dimensional gel electrophoresis, microsequencing and immunodetection Electrophoresis 21 5 2000 935 948
41. K. Weldingh, I. Rosenkrands, S. Jacobsen, P.B. Rasmussen, M.J. Elhay, and P. Andersen Two-dimensional electrophoresis for analysis of Mycobacterium tuberculosis culture filtrate and purification and characterization of six novel proteins Infect Immun 66 8 1998 3492 3500
42. T. Jaeger, H. Budde, L. Flohé, U. Menge, M. Singh, M. Trujillo, and R. Radi Multiple thioredoxin-mediated routes to detoxify hydroperoxides in Mycobacterium tuberculosis Arch Biochem Biophys 423 1 2004 182 191
43. B. Rho, L. Hung, J.M. Holton, D. Vigil, S. Kim, M.S. Park, T.C. Terwilliger, and J. Pédelacq Functional and structural characterization of a thiol peroxidase from Mycobacterium tuberculosis J Mol Biol 361 5 2006 850 863
44. Y. Hu, and A.R.M. Coates Acute and persistent Mycobacterium tuberculosis infections depend on the thiol peroxidase TpX PLoS ONE 4 4 2009 e5150
45. L. Pospísil, A. Kabátová, and F. Kratochvíl Peroxidázový (TPx) a hemaglutinacní test (TPHA) v sérodiagnostice syfilis Cesk Dermatol 49 6 1974 399 404
46. S.T. Cole, R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S.V. Gordon, K. Eiglmeier, S. Gas, C.E. Barry, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M.A. Quail, M.A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. Squares, J.E. Sulston, K. Taylor, S. Whitehead, and B.G. Barrell Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence Nature 393 6685 1998 537 544
47. P. Lefèvre, M. Braibant, L. de Wit, M. Kalai, D. Röeper, J. Grötzinger, J.P. Delville, P. Peirs, J. Ooms, K. Huygen, and J. Content Three different putative phosphate transport receptors are encoded by the Mycobacterium tuberculosis genome and are present at the surface of Mycobacterium bovis BCG J Bacteriol 179 9 1997 2900 2906
48. F. Vanzembergh, P. Peirs, P. Lefevre, N. Celio, V. Mathys, J. Content, and M. Kalai Effect of PstS sub-units or PknD deficiency on the survival of Mycobacterium tuberculosis Tuberculosis (Edinb) 90 6 2010 338 345
49. C. Palma, R. Spallek, G. Piccaro, M. Pardini, F. Jonas, W. Oehlmann, M. Singh, and A. Cassone The M. tuberculosis phosphate-binding lipoproteins PstS1 and PstS3 induce Th1 and Th17 responses that are not associated with protection against M. tuberculosis infection Clin Dev Immunol 2011 2011 690328
50. A. Demissie, L. Wassie, M. Abebe, A. Aseffa, G. Rook, A. Zumla, P. Andersen, and T.M. Doherty The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon Infect Immun 74 5 2006 2817 2822
51. V.M.C. Silva, G. Kanaujia, M.L. Gennaro, and D. Menzies Factors associated with humoral response to ESAT-6, 38 kDa and 14 kDa in patients with a spectrum of tuberculosis Int J Tuberc Lung Dis 7 5 2003 478 484
52. K.R. Steingart, L.L. Flores, N. Dendukuri, I. Schiller, S. Laal, A. Ramsay, P.C. Hopewell, and M. Pai Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis PLoS Med 8 8 2011 e1001062